肺肉瘤样癌独特的临床基因组特征及其与免疫治疗的关联:一项多中心回顾性研究
该多中心回顾性研究分析了三个机构和NCDB中接受免疫检查点抑制剂(ICI)治疗的转移性NSCLC患者,比较肺肉瘤样癌(PSC)与肺腺癌(LUAD)和肺鳞癌(LUSC)的临床基因组特征及治疗结局。结果显示PSC接受ICI的结局优于化疗,缓解率高于LUAD和LUSC,可能与PD-L1高表达有关,且PSC具有独特的基因组特征。
要点
- PSC接受ICI治疗的缓解率为37%至43%,高于LUAD的26%至29%和LUSC的22%至46%(p < 0.05)。
- 在MDACC和NCDB队列中,ICI治疗PSC的结局优于化疗,且ICI单药与ICI联合化疗之间无差异。
- PSC中PD-L1高表达(≥50%)占73%至77%,高PD-L1患者中各组织学亚型缓解率相似。
核心结论
- PSC接受ICI治疗的结局优于其他治疗,可能由PD-L1高表达驱动。
- 基因组分析显示PSC与LUAD相比具有独特的基因组景观。
研究设计与样本
- 多中心回顾性研究,纳入三个机构和美国国家癌症数据库(NCDB)中接受ICI单药或联合化疗的转移性NSCLC患者。
- 共分析4841例患者,包括来自三个机构的165例接受ICI治疗的PSC和来自NCDB的201例PSC。
- 在MDACC队列中,PSC 65例(4.3%),LUAD 1138例(75.1%),LUSC 312例(20.6%)。
主要发现
- PSC患者年龄更大,更常见转移性疾病。
- 在MDACC和NCDB队列中,ICI治疗PSC的结局优于化疗。
- 在PSC患者中,ICI单药与ICI联合化疗的结局无差异。
- 三个机构队列中,接受ICI的PSC缓解率为37%至43%,LUAD为26%至29%,LUSC为22%至46%(p < 0.05)。
- PSC中PD-L1≥50%者占73%至77%;高PD-L1患者中各组织学亚型缓解率相似;TMB在PSC与LUAD或LUSC间相似,且与ICI结局无关。
关键数值与推荐
- PSC肿瘤中TP53、NF1、NF2和NRAS富集,而STK11和KEAP1相对缺失(与LUAD相比)。
- 个案观察显示,在MET外显子14跳跃或KRAS G12C的PSC患者中,ICI结局相对优于靶向治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pulmonary sarcomatoid carcinoma (PSC) is a rare NSCLC subtype with poor prognosis. Outcomes to immune checkpoint inhibitors (ICIs) and genomic features in PSC remain underexplored compared with other NSCLC subtypes. METHODS: Patients from three institutions and the National Cancer Database (NCDB) with metastatic NSCLC treated with ICI alone or with chemotherapy were identified. Clinicogenomics and treatment outcomes were compared across PSC, lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC). RESULTS: We analyzed 4841 patients including 165 PSC cases treated with ICI-based therapy from three institutions and 201 PSC from NCDB. In MDACC, 65 (4.3%) were PSC, 1138 (75.1%) LUAD, and 312 (20.6%) LUSC. Patients with PSC were older and more likely to present with metastatic disease. In both the MDACC and NCDB cohorts, ICIs resulted in better outcomes for patients with PSC compared with chemotherapy. In these patients, there was no difference in outcome between ICI-monotherapy and ICI-chemotherapy. Across the three institutional cohorts, 37% to 43% of patients with PSC who received ICIs were responders, compared with 26% to 29% in LUAD and 22% to 46% in LUSC (p < 0.05). Improved ICI outcomes in PSC appeared driven by high PD-L1 (≥50% in 73%-77% cases). Among patients with high PD-L1, response rates were similar across histologic subtypes. Conversely, TMB was similar in PSC compared with LUAD or LUSC and was not associated with ICI outcomes. Across cohorts, PSC tumors were enriched for TP53, NF1, NF2, and NRAS, with relative depletion of STK11 and KEAP1 compared with LUAD. Case observation revealed relatively better outcomes to ICI than targeted therapies in patients with PSC with MET exon 14 skipping or KRAS G12C. CONCLUSION: PSC exhibits improved outcomes to ICI relative to other therapies, potentially driven by high PD-L1 expression. Genomic analysis highlights a distinct genomic landscape of PSC when compared with LUAD.
引用
- Hong L, Di Federico A, Liu B, et al. Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study. J Thorac Oncol. 2025. PMID: 40716572. doi:10.1016/j.jtho.2025.07.121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。